title: Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model.
abstract: The purpose of this study was to test the mutant selection window (MSW) hypothesis with Escherichia coli exposed to levofloxacin in a rabbit model and to compare in vivo and in vitro exposure thresholds that restrict the selection of fluoroquinolone-resistant mutants. Local infection with E. coli was established in rabbits, and the infected animals were treated orally with various doses of levofloxacin once a day for five consecutive days. Changes in levofloxacin concentration and levofloxacin susceptibility were monitored at the site of infection. The MICs of E. coli increased when levofloxacin concentrations at the site of infection fluctuated between the lower and upper boundaries of the MSW, defined in vitro as the minimum inhibitory concentration (MIC99) and the mutant prevention concentration (MPC), respectively. The pharmacodynamic thresholds at which resistant mutants are not selected in vivo was estimated as AUC24/MPC > 20 h or AUC24/MIC > 60 h, where AUC24 is the area under the drug concentration time curve in a 24-h interval. Our finding demonstrated that the MSW existed in vivo. The AUC24/MPC ratio that prevented resistant mutants from being selected estimated in vivo is consistent with that observed in vitro, indicating it might be a reliable index for guiding the optimization of antimicrobial treatment regimens for suppression of the selection of antimicrobial resistance.
authors.affiliation: Department of Respiratory Diseases, PLA General Hospital, 28 FuXing Road, Beijing, 100853, China.
authors.forename: W
authors.initials: W
authors.lastname: Ni
authors.forename: X
authors.initials: X
authors.lastname: Song
authors.forename: J
authors.initials: J
authors.lastname: Cui
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000235:genetics; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D064704:Levofloxacin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D064704:Levofloxacin
references.citation: J Antimicrob Chemother. 2003 Jul;52(1):61-4
references.pmid: 12805268
references.citation: Int J Antimicrob Agents. 2002 Jul;20(1):44-9
references.pmid: 12127710
references.citation: J Antimicrob Chemother. 1996 Sep;38(3):443-55
references.pmid: 8889719
references.citation: J Antimicrob Chemother. 2008 Sep;62(3):434-6
references.pmid: 18544596
references.citation: J Antimicrob Chemother. 2004 Feb;53(2):252-7
references.pmid: 14688048
references.citation: Int J Antimicrob Agents. 2012 Dec;40(6):516-20
references.pmid: 23068598
references.citation: Antimicrob Agents Chemother. 2007 Nov;51(11):3810-5
references.pmid: 17664314
references.citation: Antimicrob Agents Chemother. 2012 Apr;56(4):1680-5
references.pmid: 22232279
references.citation: Int J Antimicrob Agents. 2011 Mar;37(3):253-5
references.pmid: 21236644
references.citation: Antimicrob Agents Chemother. 2009 Jan;53(1):235-41
references.pmid: 18838592
references.citation: Antimicrob Agents Chemother. 1996 Apr;40(4):879-85
references.pmid: 8849244
references.citation: J Infect Dis. 2006 Dec 1;194(11):1601-8
references.pmid: 17083047
references.citation: Clin Infect Dis. 2001 Sep 15;33 Suppl 3:S147-56
references.pmid: 11524712
references.citation: Antimicrob Agents Chemother. 2001 Mar;45(3):794-9
references.pmid: 11181363
references.citation: J Antimicrob Chemother. 2005 Jun;55(6):938-43
references.pmid: 15860549
references.citation: J Antimicrob Chemother. 2012 Nov;67(11):2700-6
references.pmid: 22809703
references.citation: J Antimicrob Chemother. 2003 Oct;52(4):616-22
references.pmid: 12951352
references.citation: Antimicrob Agents Chemother. 2011 May;55(5):2409-12
references.pmid: 21343454
references.citation: Antimicrob Agents Chemother. 2010 Dec;54(12):5214-21
references.pmid: 20855738
references.citation: J Antimicrob Chemother. 2012 Sep;67(9):2207-12
references.pmid: 22653817
references.citation: Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):353-6
references.pmid: 20119677
references.citation: Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):423-30
references.pmid: 21761126
references.citation: Antimicrob Agents Chemother. 2007 Nov;51(11):4163-6
references.pmid: 17709467
references.citation: Antimicrob Agents Chemother. 2000 Apr;44(4):814-20
references.pmid: 10722475
references.citation: J Antimicrob Chemother. 2007 Oct;60(4):795-801
references.pmid: 17635875
references.citation: Int J Antimicrob Agents. 2004 Aug;24(2):173-7
references.pmid: 15288317